Холестериновая эмболия внутрипочечных артерий – реальная причина острого повреждения почек


Обсуждаются факторы риска, течение и исходы холестериновой эмболии внутрипочечных артерий и артериол.

Литература


1. Mayo R.R., Swartz R.D. Redefining the incidence of clinically detectable atheroembolism. Am. J. Med. 1996; 100(5): 524–529.
2. Lai C.K., Randhawa P.S. Cholesterol embolization in renal allografts: a clinicopathologic study of 12 cases. Am. J. Surg. Pathol. 2007; 31(4): 536–545.
3. Scolari F., Tardanico R., Pola A. et al. Cholesterol crystal embolic disease in renal allografts. J. Nephrol. 2003; 16(1): 139–143.
4. Saklayen M.G., Gupta S., Suryaprasad A., Azmeh W. Incidence of atheroembolic renal failure after coronary angiography. A prospective study. Angiology. 1997;48(7): 609–613.
5. Fries C., Roos M., Gaspert A. et al. Atheroembolic disease--a frequently missed diagnosis: results of a 12-year matched-pair autopsy study. Medicine (Baltimore). 2010; 89(2): 126–132.
6. Staessen J.A., Gasowski J., Wang J.G. et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865–872.
7. Stamler J., Stamler R., Neaton J. Blood pressure, systolic and diastolic, and cardiovascular risk: US population data. Arch. Intern. Med. 1993; 153: 598–615.
8. Vaughan C.J., Delanty N. Hypertensive emergencies. Lancet 2000; 356: 411–417.
9. Rupprecht H. Postinterventional cholesterol crystal embolization. Dtsch. Med. Wochenschr. 2007; 132(36): 1833–1836.
10. Charytan D.M., Marulkar S. Relationship of aortic atherosclerosis to acute renal failure following cardiac surgery. J. Nephrol. 2006; 19(5): 628–633.
11. Fuks D.F., Griguoli R.E., Borracci R.A., Sala C. Cholesterol embolization following coronary angioplasty. Rev. Port. Cardiol. 1992; 11(12): 1089–1091.
12. Thériault J., Agharazzi M., Dumont M. et al. Atheroembolic renal failure requiring dialysis: potential for renal recovery? A review of 43 cases. Nephron Clin. Pract. 2003; 94(1):c11–c18.
13. Machino-Ohtsuka T., Seo Y., Ishizu T. et al. Combined assessment of carotid vulnerable plaque, renal insufficiency, eosinophilia, and hs-CRP for predicting risky aortic plaque of cholesterol crystal embolism. Circ. J. 2010; 74(1): 51–58.
14. Vidt D.G., Eisele G., Gephardt G.N. et al. Atheroembolic renal disease: association with renal arterial stenosis. Cleve. Clin. J. Med. 1989; 56(4): 407–413.
15. Чазов Е.И., Мухин Н.А., Жарова Е.А., Фомин В.В. Острая почечная недостаточность, обусловленная холестериновой эмболией внутрипочечных артерий после коронароангиографии: успех лечения глюкокортикостероидами. Тер. арх. 2008; 8: 54–57.
16. Alcazar J.M., Rodicio J.L. Ischemic nephropathy: clinical characteristics and treatment. Am. J. Kidney Dis. 2000; 36(5): 883–893.
17. Мухин Н.А., Фомин В.В. Атеросклеротический стеноз почечных артерий. Чазов Е.И., Кухарчук В.В., Бойцов С.А. (ред.) Руководство по атеросклерозу и ишемической болезни сердца. М., MediaMedica, 2007: 248–273.
18. Hyman B.T., Landas S.K., Ashman R.F. et al. Warfarin-related purple toes syndrome and cholesterol microembolization. Am. J. Med. 1987; 82: 1233–1237.
19. Feder W., Auerbach R. “Purple toes”: an uncommon sequela of oral coumadin drug therapy. Ann. Intern. Med. 1961; 55: 911–917.
20. Schwartz M.W., McDonald G.B. Cholesterol embolization syndrome. Occurrence after intravenous streptokinase therapy for myocardial infarction. J.A.M.A. 1987;258(14): 1934–1935.
21. Wong F.K., Chan S.K., Ing T.S. et al. Acute renal failure after streptokinase therapy in a patient with acute myocardial infarction. Am. J. Kidney Dis. 1995; 26(3): 508–510.
22. Hitti W.A., Anderson J. Cholesterol emboli-induced renal failure and gastric ulcer after thrombolytic therapy. South. Med. J. 2005; 98(2): 235–237.
23. Gupta B.K., Spinowitz B.S., Charytan C., Wahl S.J. Cholesterol crystal embolization-associated renal failure after therapy with recombinant tissuetype plasminogen activator. Am. J. Kidney Dis. 1993; 21(6): 659–662.
24. Gallego Page J.C., Gómez Honrubia M.C., Gallardo López A. et al. Skin lesions and renal failure after myocardial infarction. Rev. Esp. Cardiol. 2001; 54(11): 1339–1342.
25. Fukumoto Y., Tsutsui H., Tsuchihashi M., Cholesterol Embolism Study (CHEST) Investigators. The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study. J. Am. Coll. Cardiol. 2003; 42(2): 211–216.
26. Modi K.S., Rao V.K. Atheroembolic renal disease. J. Am. Soc. Nephrol. 2001; 12: 1781–1787.
27. Kasinath B.S., Lewis E.J. Eosinophilia as a clue to the diagnosis of atheroembolic renal disease. Arch. Intern. Med. 1987; 147: 1384–1385.
28. Greenberg A., Bastacky S.I., Iobal A. et al. Focal segmental glomerulosclerosis associated with nephrotic syndrome in cholesterol atheroembolism: clinicopathological correlations. Am. J. Kidney Dis. 1997; 29: 334–344.
29. Maejima H., Noguchi T., Tanei R. Cholesterol embolism associated with MPO-ANCA. Eur. J. Dermatol. 2010; 20(4): 539–540.
30. Goldman M., Thoua Y., Dhaene M, Toussaint C. Necrotising glomerulonephritis associated with cholesterol microemboli. Br. Med. J. 1985; 290: 205–206.
31. Aviles B., Ubeda I., Blanco J, Barrientos A. Pauci-immune extracapillary glomerulonephritis and atheromatous embolization. Am. J. Kidney Dis. 2002; 40(4): 847–851.
32. Jones D.B., Iannaccone P.M. Atheromatous emboli in renal biopsies. Am. J. Pathol. 1975; 78: 261–271.
33. Ribera Pibernat M., Bigatà Viscasillas X., Fuentes González M.J. et al. Cholesterol embolism disease: study of 16 cases. Rev. Clin. Esp. 2000; 200(12): 659–663.
34. Thadhani R.I., Camargo C.A., Xavier R.J. et al. Atheroembolic renal failure after invasive procedures. Natural history based on 52 histologically proven cases. Medicine (Baltimore). 1995; 74(6): 350–358.
35. Fine M.J., Kapoor W., Falanga V. Cholesterol crystal embolization: a review of 221 cases in the English literature. Angiology. 1987; 38(10): 769–784.
36. Tanaka M., Matsuo K., Shoda H. et al. Severe hyperreninemic hypertension associated with spontaneous renal cholesterol crystal embolization. Clin. Exp. Nephrol. 2004; 8(2): 150–154.
37. Wilson D.M., Salazer T.L., Farkouh M.E. Eosinophiluria in atheroembolic renal disease. Am. J. Med. 1991; 91(2): 186–189.
38. Stabellini N., Cerretani D., Russo G. et al. Renal atheroembolic disease: evaluation of the efficacy of corticosteroid therapy. G. Ital. Nefrol. 2002; 19(1): 18–21.
39. Hasegawa M., Kawashima S., Shikano M. et al. The evaluation of corticosteroid therapy in conjunction with plasma exchange in the treatment of renal cholesterol embolic disease. A report of 5 cases. Am. J. Nephrol. 2000; 20(4): 263–267.
40. Nakayama M., Izumaru K., Nagata M. et al. The effect of low-dose corticosteroids on short- and long-term renal outcome in patients with cholesterol crystal embolism. Ren. Fail. 2011; 33(3): 298–306.
41. Stabellini N., Cerretani D., Russo G. et al. Renal atheroembolic disease: evaluation of the efficacy of corticosteroid therapy. G. Ital. Nefrol. 2002; 19(1): 18–21.
42. Yücel A.E., Kart-Köseoglu H., Demirhan B., Ozdemir F.N. Cholesterol crystal embolization mimicking vasculitis: success with corticosteroid and cyclophosphamide therapy in two cases. Rheumatol. Int. 2006;
26(5): 454–460.
43. Cabili S., Teachman I., Goor Y. Reversal of gangrenous lesions in the blue toe syndrome with lovastatin – a case report. Angiology 1993; 44: 821–825.
44. Woolfson R.G., Lachman H. Improvement in renal cholesterol emboli syndrome after simvastatin.Lancet 1998; 351: 1331–1332.
45. Kazancioğlu R., Erkoç R., Bozfakioğlu S. et al. Clinical outcomes of renal cholesterol crystal embolization. J. Nephrol. 1999; 12(4): 266–269.
46. Hara S., Asada Y., Fujimoto S. et al. Atheroembolic renal disease: clinical findings of 11 cases. J. Atheroscler. Thromb. 2002; 9(6): 288–291.


Похожие статьи


Бионика Медиа